Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia

Martinez, VJS; Buonincontro, B; Cassarino, C; Bernatowiez, J; Colado, A; Cordini, G; Custidiano, MD; Mahuad, C; Pavlovsky, MA; Bezares, RF; Favale, NO; Vermeulen, M; Borge, M; Giordano, M; Gamberale, R

Gamberale, R (通讯作者)，Acad Nacl Med ANM, Consejo Nacl Invest Cient & Tecn CONICET, Lab Inmunol Oncol, Inst Med Expt IMEX, Buenos Aires, Argentina.;Gamberale, R (通讯作者)，UBA, Fac Med, Dept Microbiol Parasitol & Inmunol, Buenos Aires, Argentina.

FRONTIERS IN ONCOLOGY, 2023; 13 ():

Abstract

The treatment of chronic lymphocytic leukemia (CLL) patients with venetoclax-based regimens has demonstrated efficacy and a safety profile, but the em......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索